Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2008
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
Sith Sathornsumetee, Yiting Cao, Jennifer E Marcello, et al.
Molecular Cancer Therapeutics
|
June 24, 2004
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility
Mark D Hjelmeland, Anita B Hjelmeland, Sith Sathornsumetee, et al.
Brain Pathology (Zurich, Switzerland)
|
August 13, 2023
Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas
Thidathip Wongsurawat, Piroon Jenjaroenpun, Panatna Anekwiang, et al.
Neuro-Oncology
|
August 19, 2010
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee, Annick Desjardins, James J Vredenburgh, et al.
Cancer
|
February 29, 2012
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
David A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J Vredenburgh, Annick Desjardins, James E Herndon, et al.
Journal of Neuro-Oncology
|
October 15, 2011
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
David A Reardon, James E Herndon, Katherine Peters, et al.
Cancer Research
|
September 5, 2006
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma
Sith Sathornsumetee, Anita B Hjelmeland, Stephen T Keir, et al.
Neuro-Oncology
|
November 17, 2006
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
Michael A Badruddoja, Kara Penne, Annick Desjardins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
Annick Desjardins, David A Reardon, James E Herndon, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2008
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
Sith Sathornsumetee, Yiting Cao, Jennifer E Marcello, et al.
Molecular Cancer Therapeutics
|
June 24, 2004
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility
Mark D Hjelmeland, Anita B Hjelmeland, Sith Sathornsumetee, et al.
Brain Pathology (Zurich, Switzerland)
|
August 13, 2023
Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas
Thidathip Wongsurawat, Piroon Jenjaroenpun, Panatna Anekwiang, et al.
Neuro-Oncology
|
August 19, 2010
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee, Annick Desjardins, James J Vredenburgh, et al.
Cancer
|
February 29, 2012
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
David A Reardon, Annick Desjardins, James J Vredenburgh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 24, 2007
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J Vredenburgh, Annick Desjardins, James E Herndon, et al.
Journal of Neuro-Oncology
|
October 15, 2011
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients
David A Reardon, James E Herndon, Katherine Peters, et al.
Cancer Research
|
September 5, 2006
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma
Sith Sathornsumetee, Anita B Hjelmeland, Stephen T Keir, et al.
Neuro-Oncology
|
November 17, 2006
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
Michael A Badruddoja, Kara Penne, Annick Desjardins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
Annick Desjardins, David A Reardon, James E Herndon, et al.
Page
of 6